Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Microbix Biosystems. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Microbix Biosystems's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Microbix Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Microbix Biosystems's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Microbix Biosystems's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Microbix Biosystems's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Microbix Biosystems is high growth as no earnings estimate data is available.
Unable to determine if Microbix Biosystems is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Microbix Biosystems's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Microbix Biosystems's finances.
The net worth of a company is the difference between its assets and liabilities.
Microbix Biosystems is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Microbix Biosystems's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Microbix Biosystems's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Cameron Groome has been the Chief Executive Officer and President of Microbix Biosystems Inc. since July 24, 2017. Mr. Groome served as the Chief Executive Officer and President of Avivagen, Inc. since March 11, 2013 until February 9, 2017. Mr. Groome served as Executive Vice-President of Corporate & Strategic Development at Bioniche Life Sciences Inc. (now known as Telesta Therapeutics Inc.) since June 27, 2006. He has more than 20 years of experience as an Equity Analyst, Industry Commentator, Investment Banker and Corporate Advisor and Industry Commentator in the Canadian life sciences industry. Mr. Groome joined Bioniche in June 2006 from a major Canadian investment dealer, where he led its life sciences investment banking activities. He is a life sciences business and finance leader. He served as Director of Investment Banking for Blackmont Capital, as Managing Director, Corporate and Investment Banking for National Bank Financial. He served as an External Advisor to the Board of Directors of Trillium Therapeutics. He served as an Equity Analyst of National Bank Financial, Inc., Research Division and Crédit Suisse AG, Research Division and as an Analyst at First Marathon Securities, Ltd., Research Division and Gleacher & Company, Inc., Research Division. He serves as Director of ScarX Therapeutics Inc. He has been an Independent Director of Microbix Biosystems Inc. since March 8, 2012. He served as a Director of Avivagen Inc. since April 24, 2013 until February 9, 2017. He is a member of the Life Sciences Advisory Board for Canada’s Department of Foreign Affairs and International Trade. Mr. Groome holds a Bachelor of Commerce, Finance and Marketing from Concordia University (Montréal, Québec).
Cameron's compensation has been consistent with company performance over the past year.
Cameron's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Microbix Biosystems management team is about average.
Founder & Executive Chairman
Chief Financial Officer
Senior Vice President of Sales
Senior Vice President of Scientific Affairs
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Microbix Biosystems board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Founder & Executive Chairman
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Microbix Biosystems insiders in the past 3 months, but not in substantial volumes.
Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide. The company produces infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry; controls for diagnostic assays. Its infectious disease antigens also used in controls for diagnostic assays, basic and applied research in virology, microbiology, cell biology, immunology, and pathology, or for vaccine and antiviral research and development. The company also provides quality assessment products, including PROCEEDx Verification/Validation samples, which are research use only products for use in test system IQ/OQ/PQ, verification/validation, and training; PTDx proficiency testing products; and REDx Controls, which are designed to enhance the diagnostic quality outcome by early detection of the deviations from desired assay performance. In addition, it develops Kinlytic Urokinase for injection, a thrombolytic biologic drug used to treat blood clots; and LumiSort cell-sorting, a technology for sorting of particles that could be used to enrich cell populations of interest, such as in sexing semen. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.